Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NOISYXETINE noradrenergic modulation of learning dynamics
2025-520959-90-00Phase 2Authorised
- Sponsor
- GHU Paris psychiatrie & neurosciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of atomoxetine (2 arms), sponsored by GHU Paris psychiatrie & neurosciences. Planned start Nov 2025; status: authorised.
02
Drugs
atomoxetine
Beyond the preview
Go deeper on 2025-520959-90-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520959-90-00.